ADC Therapeutics S.A.
- ADCT
- NYSE
- Biotechnology
- Antibody-Drug Conjugates
- Oncology Therapeutics
$1.44
Today +3.23%Quote Oct 19, 2026, 08:00 PM UTC
+37.14%over the last month
Max drawdown −24.7%From 1-month high −22.6%3 months +13.4%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About ADC Therapeutics
ADC Therapeutics S.A. operates as a commercial-stage biotechnology company, focused on developing antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors.
Where the money comes from
Q2 2026 revenue $19.2M
- Product$18.6M96.8%
- Royalty Revenue$614,0003.2%
Sector
Healthcare
Industry
Biotechnology
Exchange
NYSE
Employees
191
Founded
2011
Market value
$183.8M
Quote Oct 19
Floor
$1.39
3.3% below price
Resistance
$1.56
8.1% above price
Price vs analyst targets
12 analysts
Lowest target
$2.00Highest target
$5.00
$2.00Highest target
$5.00
- Price $1.44
- Average target $3.50
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 143% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about ADCTPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free